Chronic Lithium Administration Enhances Noradrenergic Responses to Intravenous Administration of the α2 Antagonist Idazoxan in Healthy Volunteers

Journal of Clinical Psychopharmacology

Volumn 24, Issue 2, 2004, Pages 150-154

  Özerdem, Ayşegül ^a   Schmidt, Mark E ^b   Manji, Husseini K ^c   Risinger, Robert C ^d   Potter, William Z ^e  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDAZOXAN; LITHIUM; LITHIUM CARBONATE; NORADRENALIN;

ADULT; ARTICLE; BIPOLAR DISORDER; CHRONIC DRUG ADMINISTRATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SYMPATHETIC TONE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ANTIMANIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; IDAZOXAN; INJECTIONS, INTRAVENOUS; LITHIUM CARBONATE; MALE; MIDDLE AGED; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-2; REGRESSION ANALYSIS; SEX CHARACTERISTICS;

EID: 1642281077     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000115667.45074.9f     Document Type: Article

References (40)

1. Bunney WE, Garland-Bunney BL. Mechanisms of action of lithium in affective illness: basic and clinical implications. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987:553-565.
2. Wood AJ, Goodwin GM. A review of the biochemical and neuropharmacological actions of lithium. Psychol Med. 1987;17:579-600.
3. Ahluwalia P, Singhal RL. Effect of low dose lithium administration and subsequent withdrawal on biogenic amines in rat brain. Br J Pharmacol. 1980;71:601-607.
4. Ebstein RP, Lerer B, Shlaufman M, et al. The effect of repeated electroconvulsive shock treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. Cell Mol Neurobiol. 1983;3(3):191-200.
5. 2 receptor and α adrenoceptor mediated function in mice. Psychopharmacology. 1986;90:482-487.
6. Swann AC, Kouslow SH, Katz MM, et al. Lithium carbonate treatment of mania. Arch Gen Psychiatry. 1987;44:345-354.
7. Linnoila M, Karoum F, Rosenthal N, et al. Electroconvulsive treatment and lithium carbonate. Arch Gen Psychiatry. 1983;40:677-680.
8. Murphy DL, Lake CR, Slater S, et al. Psychoactive drug effects on plasma norepinephrine and plasma dopamine β-hydroxylase in man. In: Kodin E, Kopin IJ, Barchas J, eds. Catecholamines: Basic and Clinical Frontiers. Elmsford, NY: Pergamon Press; 1979:918-920.
9. Grof E, Brown M, Grof P, et al. Effects of lithium administration on plasma catecholamines. Psychiatry Res. 1986;19:87-92.
10. Rudorfer MV, Karoum F, Ross RJ, et al. Differences in lithium effects in depressed and healthy subjects. Clin Pharmacol Ther. 1985;37:66-71.
11. Manji HK, Hsiao JK, Risby ED, et al. The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry. 1991;48:505-512.
12. Poirier-Litre MF, Loo H, Dennis T, et al. Lithium treatment increases norepinephrine turnover in the plasma of healthy subjects. Arch Gen Psychiatry. 1993;50:72-73.
13. Schatzberg AF, Cole JO, eds. Mood stabilizers. In: Manual of Clinical Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1991:145-183.
14. Langer SZ. Presynaptic regulation of the release of catecholamines. Biochem Pharmacol. 1974;23:1793-1800.
15. Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992;6(3):832-839.
16. Smith DF. Lithium attenuates clonidine-induced hypoactivity: further studies in inbred mouse strains. Psychopharmacology. 1988;94:428-430.
17. Goodnick PJ, Meltzer HY. Neurochemical changes during discontinuation of lithium prophylaxis. I. Increases in clonidine-induced hypotension. Biol Psychiatry. 1984;19(6):883-889.
18. q/11α) in rat brain. Neurosci Abstr. 1995;21:731-738.
19. Brambilla F, Catalano M, Lucca A, et al. Effect of lithium on the GH-clonidine test in affective disorders. Eur J Clin Pharmacol. 1988;35(6): 601-605.
20. 2 adrenoceptors in major affective disorder. Effect of long term lithium carbonate treatment. Arch Gen Psychiatry. 1986;43:51-57.
21. Risby ED, Hsiao JK, Manji HK, et al. The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and β-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry. 1991;48:513-524.
22. Hsiao JK, Manji HK, Chen G, et al. Lithium administration modulates platelet Gi in humans. Life Sci. 1991;50:227-233.
23. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984;41:751-763.
24. Goldstein DS, Grossman E, Listwak S, et al. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension. 1991;18(suppl 5):III40-III48.
25. Doxey JC, Roach AG, Smith CF. Studies on RX 781094: a selective, potent, and specific antagonist of alpha2-adrenoceptors. Br J Pharmacol. 1983;78:489-505.
26. 2 antagonist) increases plasma norepinephrine and is an antidepressant. Paper presented at: Society of Biological Psychiatry 44th Annual Meeting; 1993; San Francisco.
27. Cooper TB, Bergner PE, Simpson GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry. 1973;130: 601-603.
28. Mefford IN, Ward MM, Miles L, et al. Determination of plasma catecholamines and free 3,4-dihydroxyphenylacetic acid in continuously collected human plasma by high performance liquid chromatography with electrochemical detection. Life Sci. 1981;28:477-483.
29. Mefford IN, Ota M, Stipetic M, et al. Application of a novel cation-exchange reagent, igepon T-77 (N-methyl oleoyl taurate), to microbore separations of alumina extracts of catecholamines from cerebrospinal fluid, plasma, urine and brain tissue with amperometric detection. J Chromatogr. 1987;420:241-251.
30. Schimidt ME, Matochik JA, Goldstein DS, et al. Gender differences in brain metabolic and plasma catecholamine responses to alpha 2-adrenoceptor blockade. Neuropsychopharmacology. 1997;16(4): 298-310.
31. Schimidt ME, Risinger RC, Hauger RL, et al. Responses to alpha 2 adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrinology. 1997;22(3):177-188.
32. 3H] Idazoxan in rat brain. J Pharmacol Exp Ther. 1987;241:1092-1098.
33. 2-adrenoceptor stimulation and antagonism in man. Clin Sci. 1985;68(suppl 10):137s-139s.
34. Grossman E, Rea RF, Hoffman A, et al. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Physiol. 1991;260(1 pt 2):R142-R147.
35. Krystal JH, McDougle CJ, Woods SW, et al. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology (Berl). 1992;108:313-319.
36. 2 adrenergic receptor antagonist SL 84.0418 in healthy subjects. Clin Pharmacol Ther. 1994; 55:338-345.
37. Mochida S. Acetylcholine elicits metabolically mediated M2-muscarinic hyperpolarization in isolated rabbit sympathetic neurons. Jpn J Physiol. 1990;40:189-204.
38. Özerdem A, Kürklü MK, Yíldíz A, et al. Noradrenergic function in a group of euthymic drug free bipolar patients. J Affect Disord. 2002; 68(1):129.
39. Heal DJ, Butler SA, Prow MR, et al. Quantification of presynaptic alpha 2-adrenoceptors in rat brain after short-term DSP-4 lesioning. Eur J Pharmacol. 1993;249(1):37-41.
40. Schmidt ME, Matochid JA, Risinger RC, et al. Regional brain glucose metabolism following acute alpha-2 blockade by idazoxan. Clin Pharmacol Ther. 1995;57:684-695.